These are not the branded products Wegovy, Ozempic, Zepbound, or Mounjaro
An intensive discussion on the pancreatic safety of incretin-based therapies initiated by publications of a single group have led to a thorough evaluation of non-clinical and clinical data by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) (3845)
Risks Fortunately for their fans, these supplements are generally considered low risk
The peptide mimics endogenous alpha-MSH but with improved stability and receptor selectivity
Soluble aggregates are usually reversible: e.g., by altered solution conditions such as changing temperature or osmotic strength or by mild physical disruption such as swirling or filtration
June 10 Product: Ipsen and Genfits Iqirvo Indication: Primary biliary cholangitis Monday, the FDA approved the first new drug in nearly a decade for primary biliary cholangitis: Ipsen and Genfits Iqirvo